Europe Taking the Lead in Reducing Animal Testing for Excipients

March 12, 2007
Europe has been in the forefront of in vitro drug testing method development.  But today, in news that my children will celebrate, I learned that an offshoot of the REACH product safety program in Europe could reduce the need for animal testing of pharmaceutical excipients. Ten leading pharma companies, including AstraZeneca, GSK, Johnson & Johnson, Sanofi-Aventis and Novo Nordisk, will be sharing data, using software developed by the U.K. company Lhasa, that could reduce the need for animal testing.  More on this from InPharma Technologist. (But the last, brief word from two who were spared to focus on bigger things). -AMS
Europe has been in the forefront of in vitro drug testing method development.  But today, in news that my children will celebrate, I learned that an offshoot of the REACH product safety program in Europe could reduce the need for animal testing of pharmaceutical excipients. Ten leading pharma companies, including AstraZeneca, GSK, Johnson & Johnson, Sanofi-Aventis and Novo Nordisk, will be sharing data, using software developed by the U.K. company Lhasa, that could reduce the need for animal testing.  More on this from InPharma Technologist. (But the last, brief word from two who were spared to focus on bigger things). -AMS
About the Author

pharmamanufacturing | pharmamanufacturing